Canadian Economic Evaluation of Budesonide-Formoterol as Maintenance and Reliever Treatment in Patients with Moderate to Severe Asthma

Canadian Economic Evaluation of Budesonide-Formoterol as Maintenance and Reliever Treatment in Patients with Moderate to Severe Asthma

OBJECTIVES: To compare the cost-effectiveness of budesonide-formoterol in a single inhaler used as both maintenance and reliever medication versus clinician-directed titration of salmeterol-fluticasone as maintenance medication, plus salbutamol taken as needed, in controlling asthma in adults and ad...

Full description

Saved in:

Bibliographic Details
Main Authors:	Elizabeth Miller, Malcolm R Sears, Andrew McIvor, Anna Liovas
Format:	Article
Language:	English
Published:	Wiley 2007-01-01
Series:	Canadian Respiratory Journal
Online Access:	http://dx.doi.org/10.1155/2007/560819
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

COMPARATIVE EFFICACY OF INHALED DRUGS FORMOTEROL / BECLOMETHASONE AND FORMOTEROL / BUDESONIDE AND BRONCHIAL ASTHMA
by: V. A. Nikitin, et al.
Published: (2016-03-01)

Real-Life Effectiveness of Budesonide/Formoterol as Maintenance and Reliever Treatment via the Elpenhaler® Device in Patients with Asthma: The NOTOS Observational Study
by: Gogali A, et al.
Published: (2025-04-01)

Beclometasone Dipropionate/Formoterol Fumarate is Similarly Effective to Budesonide/Formoterol Fumarate in Chinese Patients with COPD: The FORSYYN Double-Blind, Randomised Study
by: Fuqiang Wen, et al.
Published: (2024-12-01)

Role of inhaled corticosteroids/formoterol in relieving acute asthma as compared to traditional salbutamol in children 6 to 11 years old on maintenance and reliever therapy step 3 and above as per the Global Initiative for Asthma guideline
by: Danish Abdul Aziz, et al.
Published: (2025-06-01)

Comparative Efficacy of Budesonide/Formoterol Versus Fluticasone/Salmeterol in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis
by: Nan Shang, et al.
Published: (2024-12-01)

Characteristics of Patients Receiving Budesonide/Glycopyrronium/Formoterol for Chronic Obstructive Pulmonary Disease in Spain: The AURA Study
by: Calle Rubio M, et al.
Published: (2025-04-01)

Mortality among Subjects with Chronic Obstructive Pulmonary Disease or Asthma at Two Respiratory Disease Clinics in Ontario
by: Murray M Finkelstein, et al.
Published: (2011-01-01)

Chromium and formoterol therapy for obesity-induced asthma in rats
by: Rania T. Ibrahim, et al.
Published: (2025-04-01)

Comparing the immediate Bronchodilatory effects of Salbutamol versus Formoterol: A General Practice Study in Patients with Moderate Asthma
by: C.M. Kruger
Published: (2001-06-01)

The Role of Omalizumab in the Treatment of Severe Allergic Asthma
by: Kenneth R Chapman, et al.
Published: (2006-01-01)

APPLICATION OF BUDESONIDE IN BREASTFEEDING MOTHERS WITH BRONCHIAL ASTHMA
by: E.A. Vishneva, et al.
Published: (2009-10-01)

Tiotropium for the Treatment of Asthma: Patient Selection and Perspectives
by: V. Madhu Chari, et al.
Published: (2018-01-01)

Effects of Budesonide and Fluticasone Propionate in Pediatric Asthma Patients
by: Lin-Yu Kuo, et al.
Published: (2010-02-01)

Real-Life Asthma Care in Canada
by: RA McIvor, et al.
Published: (2009-01-01)

Real-world use of inhaled corticosteroid/formoterol as needed in adults with mild asthma: the PRIME study
by: Guy Brusselle, et al.
Published: (2024-09-01)

Characteristics of Patients Initiated on Budesonide/Glycopyrronium Bromide/Formoterol Fumarate Single Inhaler Triple Therapy for the Treatment of Chronic Obstructive Pulmonary Disease: A Population-Based Observational Study
by: Deslee G, et al.
Published: (2025-04-01)

Comparison of Budesonide Turbuhaler with Budesonide Aqua in the Treatment of Seasonal Allergic Rhinitis
by: William H Yang, et al.
Published: (1998-01-01)

Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study
by: Alberto Papi, et al.
Published: (2021-11-01)

Inhaled Formoterol-Fluticasone Single Inhaler Therapy in Asthma: Real-World Efficacy, Budget Impact, and Potential to Improve Adherence
by: V. Rajesh, et al.
Published: (2020-01-01)

Anti-inflammatory reliever therapy (AIR) for asthma
by: Mark L. Levy, et al.
Published: (2024-09-01)

Maintenance oral steroids are not required in severe asthma
by: Emma Rebecca Graham, et al.
Published: (2024-12-01)

Tobacco Control and Nicotine Addiction in Canada: Current trends, Management and Challenges
by: Andrew McIvor
Published: (2009-01-01)

Single inhaler with beclometasone, formoterol, and glycopyrronium versus triple therapies in adults with uncontrolled asthma: a systematic review and meta-analysis
by: Fulvio Braido, et al.
Published: (2025-02-01)

Budesonide in treatment of alcohol-induced severe hepatitis: results of randomized trial
by: I. I. Komkova, et al.
Published: (2013-09-01)

Altered Frequency of NK Cells and Treg Cells by Astragalus Polysaccharide Combined with Budesonide in Asthma Model Mice
by: Wei Zhang, et al.
Published: (2020-01-01)

Influence of Current or Former Smoking on Asthma Management and Control
by: Louis-Philippe Boulet, et al.
Published: (2008-01-01)

The management of adults and children with moderate severity asthma
by: P.M. Jeena
Published: (2007-05-01)

Prevalence of Asthma and Asthma Severity Among Patients with Moderate–Severe Atopic Dermatitis Treated with Advanced Systemics
by: Maria O. Christensen, et al.
Published: (2025-06-01)

Budesonide for the Treatment of Inflammatory Bowel Disease
by: Gordon R Greenberg
Published: (1994-01-01)

Anti-inflammatory reliever therapy for asthma in India – Can we be SMARTer
by: Nipun Malhotra, et al.
Published: (2025-07-01)

Budesonide-incorporated inhalable lipid nanoparticles for antiTSLP nanobody mRNA delivery to treat steroid-resistant asthma
by: Jia Huang, et al.
Published: (2025-07-01)

RETRACTED ARTICLE: A comparative pulmonary pharmacokinetic study of budesonide using polymeric nanoparticles targeted to the lungs in treatment of asthma
by: Niyaz Ahmad, et al.
Published: (2020-01-01)

Inhaled Corticosteroids Should Not Be Prescribed to All Chronic Obstructive Pulmonary Disease Patients
by: Jean Bourbeau, et al.
Published: (2003-01-01)

Safety of budesonide/glycopyrronium/formoterol fumarate dihydrate delivered by HFO-1234ze versus HFA-134a in chronic obstructive pulmonary disease: a phase 3, multi-site, randomised, double-blind, parallel-group, active-comparator studyResearch in context
by: Omar S. Usmani, et al.
Published: (2025-09-01)

Preferences for Biologic Treatments: A Discrete Choice Experiment Survey of Canadians with Severe Asthma
by: Dunne JS, et al.
Published: (2025-05-01)

Budesonide Enemas for Topical Therapy of Ulcerative Colitis
by: P Rutgeerts
Published: (1990-01-01)

The Use of Budesonide in the Treatment of Autoimmune Hepatitis in Canada
by: Iman Zandieh, et al.
Published: (2008-01-01)

Comparison of extrafine and non-extrafine inhaled corticosteroids/long-acting β-agonists as maintenance and reliever therapy in asthma: a randomized open-label crossover trial
by: Sang Pyo Lee, et al.
Published: (2025-05-01)

Effects of inhaled beclometasone dipropionate/formoterol fumarate/glycopyrronium vs. beclometasone dipropionate/formoterol fumarate and placebo on lung hyperinflation and exercise endurance in chronic obstructive pulmonary disease: a randomised controlled trial
by: Henrik Watz, et al.
Published: (2024-10-01)

A Targeted-Release Formulation of Budesonide for the Treatment of IgA Nephropathy Patients With Severe Renal Impairment
by: Yan Ouyang, et al.
Published: (2025-03-01)